1. Home
  2. LUNR vs ZYME Comparison

LUNR vs ZYME Comparison

Compare LUNR & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LUNR
  • ZYME
  • Stock Information
  • Founded
  • LUNR 2013
  • ZYME 2003
  • Country
  • LUNR United States
  • ZYME United States
  • Employees
  • LUNR N/A
  • ZYME N/A
  • Industry
  • LUNR Industrial Machinery/Components
  • ZYME Biotechnology: Pharmaceutical Preparations
  • Sector
  • LUNR Industrials
  • ZYME Health Care
  • Exchange
  • LUNR Nasdaq
  • ZYME Nasdaq
  • Market Cap
  • LUNR 1.4B
  • ZYME 1.2B
  • IPO Year
  • LUNR N/A
  • ZYME 2017
  • Fundamental
  • Price
  • LUNR $12.17
  • ZYME $17.40
  • Analyst Decision
  • LUNR Buy
  • ZYME Strong Buy
  • Analyst Count
  • LUNR 6
  • ZYME 8
  • Target Price
  • LUNR $14.00
  • ZYME $24.00
  • AVG Volume (30 Days)
  • LUNR 9.4M
  • ZYME 661.8K
  • Earning Date
  • LUNR 11-13-2025
  • ZYME 11-06-2025
  • Dividend Yield
  • LUNR N/A
  • ZYME N/A
  • EPS Growth
  • LUNR N/A
  • ZYME N/A
  • EPS
  • LUNR N/A
  • ZYME N/A
  • Revenue
  • LUNR $225,977,000.00
  • ZYME $122,867,000.00
  • Revenue This Year
  • LUNR $14.43
  • ZYME $99.52
  • Revenue Next Year
  • LUNR $45.68
  • ZYME N/A
  • P/E Ratio
  • LUNR N/A
  • ZYME N/A
  • Revenue Growth
  • LUNR 42.86
  • ZYME 95.94
  • 52 Week Low
  • LUNR $6.14
  • ZYME $9.03
  • 52 Week High
  • LUNR $24.95
  • ZYME $19.50
  • Technical
  • Relative Strength Index (RSI)
  • LUNR 54.78
  • ZYME 53.55
  • Support Level
  • LUNR $10.82
  • ZYME $18.21
  • Resistance Level
  • LUNR $13.49
  • ZYME $19.10
  • Average True Range (ATR)
  • LUNR 1.27
  • ZYME 0.71
  • MACD
  • LUNR -0.11
  • ZYME -0.09
  • Stochastic Oscillator
  • LUNR 37.57
  • ZYME 36.06

About LUNR Intuitive Machines Inc.

Intuitive Machines Inc is a space exploration, infrastructure, and services company. It is a diversified space company focused on space exploration. It supplies space products and services to support sustained robotic and human exploration to the Moon, Mars, and beyond. Its products and services are offered through its four business units: Lunar Access Services, Orbital Services, Lunar Data Services, and Space Products and Infrastructure. The Company operates in one operating segment and one reportable segment underpinned by three core pillars (delivery services, data transmission services, and infrastructure as a service) that have similar capabilities, customers, and economic characteristics. Revenue is from contracts with customers of orbital and lunar access services.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: